AnGes. has been granted a patent for a method to modify a mutant CXCR4 gene associated with WHIM syndrome. The method utilizes CRISPR technology to selectively target and edit the mutant allele while preserving the expression of the functional CXCR4 protein, ensuring proper gene function. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of July 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Crispr method for modifying cxcr4 gene mutations
The patent US12031149B2 outlines a method for modifying a mutant allele of the CXCR4 gene, which is associated with WHIM syndrome, without disrupting the expression of a functional CXCR4 protein. The method employs a CRISPR nuclease in conjunction with two RNA molecules. The first RNA molecule contains a guide sequence that specifically targets a single nucleotide polymorphism (SNP) in the mutant allele, while the second RNA molecule has a non-discriminatory guide sequence that affects both the functional and mutant alleles by targeting the 3' untranslated region (UTR). This dual approach allows for the introduction of double-strand breaks in the mutant allele while preserving the functional allele, ultimately leading to the expression of only the functional CXCR4 protein in the cell.
Further claims detail the specific characteristics of the RNA molecules, including the length of the guide sequences and their targeting capabilities. The first RNA molecule can target SNP positions located in non-coding regions such as introns or promoter regions, while the second RNA molecule can target sequences near the CXCR4 polyadenylation site. The claims also specify that portions of the CXCR4 mutant allele may be excised through the action of both RNA molecules. This innovative method presents a potential therapeutic strategy for addressing genetic mutations associated with WHIM syndrome by selectively modifying the mutant allele while maintaining the functionality of the normal allele.
To know more about GlobalData’s detailed insights on AnGes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
